Published in Eur J Immunol on July 01, 2007
TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms. J Immunol (2011) 1.46
Proinflammatory progranulin antibodies in inflammatory bowel diseases. Dig Dis Sci (2014) 0.83
Specific increase in potency via structure-based design of a TCR. J Immunol (2014) 0.82
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife (2013) 5.49
Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol (2005) 5.43
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood (2007) 5.18
Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol (2002) 4.64
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol (2013) 4.50
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med (2003) 3.99
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol (2012) 3.93
Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med (2010) 3.84
The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol (2005) 3.53
Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol (2008) 3.44
Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med (2002) 3.31
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol (2003) 3.19
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol (2010) 3.17
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood (2013) 3.03
Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time. Immunity (2010) 2.82
Structure of human CD1b with bound ligands at 2.3 A, a maze for alkyl chains. Nat Immunol (2002) 2.70
A Role for cis Interaction between the Inhibitory Ly49A receptor and MHC class I for natural killer cell education. Immunity (2009) 2.62
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood (2007) 2.61
Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest (2008) 2.46
Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol (2010) 2.42
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood (2011) 2.37
Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med (2002) 2.37
The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J Exp Med (2007) 2.37
Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol (2014) 2.30
Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc Natl Acad Sci U S A (2007) 2.24
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol (2002) 2.23
Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med (2005) 2.22
Constitutively active Lck kinase in T cells drives antigen receptor signal transduction. Immunity (2010) 2.22
Immobilized chemokine fields and soluble chemokine gradients cooperatively shape migration patterns of dendritic cells. Immunity (2010) 2.18
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood (2008) 2.17
The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B*27:09. Rheumatology (Oxford) (2013) 2.14
The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods (2004) 2.13
Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study. Lancet Oncol (2009) 2.13
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol (2009) 2.13
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol (2011) 2.11
Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nat Immunol (2006) 2.11
Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood (2013) 2.09
Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med (2002) 2.07
Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses. J Immunol (2005) 2.04
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
T cell cross-reactivity and conformational changes during TCR engagement. J Exp Med (2004) 1.99
Identification of Bcl-6-dependent follicular helper NKT cells that provide cognate help for B cell responses. Nat Immunol (2011) 1.94
Tracking T cells with tetramers: new tales from new tools. Nat Rev Immunol (2002) 1.94
Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. Proc Natl Acad Sci U S A (2007) 1.92
Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold. Proc Natl Acad Sci U S A (2003) 1.89
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation (2005) 1.87
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol (2012) 1.86
Mature CD8(+) T lymphocyte response to viral infection during fetal life. J Clin Invest (2003) 1.85
T cell receptor CDR2 beta and CDR3 beta loops collaborate functionally to shape the iNKT cell repertoire. Immunity (2009) 1.85
Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc Natl Acad Sci U S A (2007) 1.84
B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo. Proc Natl Acad Sci U S A (2008) 1.83
Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol (2009) 1.83
Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet (2012) 1.81
Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun (2002) 1.80
Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc Natl Acad Sci U S A (2008) 1.80
Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood (2013) 1.79
Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood (2006) 1.76
CD169(+) macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nat Immunol (2010) 1.76
HLA-A*0201, HLA-A*1101, and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products. J Immunol (2005) 1.75
Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood (2009) 1.68
Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol (2013) 1.67
Valpha24-JalphaQ-independent, CD1d-restricted recognition of alpha-galactosylceramide by human CD4(+) and CD8alphabeta(+) T lymphocytes. J Immunol (2002) 1.66
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest (2004) 1.65
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood (2011) 1.65
The crystal structure of human CD1b with a bound bacterial glycolipid. J Immunol (2004) 1.64
Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging. PLoS One (2011) 1.62
Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci U S A (2009) 1.61
BCL6b mediates the enhanced magnitude of the secondary response of memory CD8+ T lymphocytes. Proc Natl Acad Sci U S A (2005) 1.61
HIV-specific cytotoxic T cells from long-term survivors select a unique T cell receptor. J Exp Med (2004) 1.60
Structures of an MHC class I molecule from B21 chickens illustrate promiscuous peptide binding. Immunity (2007) 1.60
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol (2008) 1.60
Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur J Dermatol (2006) 1.58
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood (2012) 1.58
Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. J Exp Med (2006) 1.57
CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens. J Exp Med (2004) 1.56
Short telomeres in aggressive non-Hodgkin's lymphoma as a risk factor in lymphomagenesis. Exp Hematol (2007) 1.55
Pivotal Advance: Heme oxygenase 1 expression by human CD4+ T cells is not sufficient for their development of immunoregulatory capacity. J Leukoc Biol (2009) 1.54
In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest (2003) 1.54
Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum (2010) 1.52
Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood (2011) 1.51
Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol (2005) 1.49
Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol (2013) 1.49
Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J Immunol (2002) 1.49
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol (2010) 1.46
Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med (2010) 1.45
Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J Immunol (2003) 1.44
Biology of CD1- and MR1-restricted T cells. Annu Rev Immunol (2014) 1.44
Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J Immunol (2006) 1.43
Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun (2007) 1.43